HER2 Inhibitors Global Market Report 2025

Description

HER2 inhibitors constitute a group of medications employed in treating HER2-low and HER2-positive breast cancers across various stages, from early to metastatic. These drugs target the HER2 receptor proteins present on breast cancer cells, hindering the reception of growth signals in HER2-positive breast cancer.

Treatments mainly consist of monotherapy and combination therapy. Monotherapy involves using a single medication for treating specific conditions or diseases. These treatments find applications in various cancer types such as squamous cell carcinoma, adenocarcinoma, large cell carcinoma, as well as breast cancer, and are utilized across healthcare sectors including hospitals, clinics, and other medical settings.

The HER2 inhibitors market research report is one of a series of new reports from The Business Research Company that provides HER2 inhibitors market statistics, including HER2 inhibitors industry global market size, regional shares, competitors with a HER2 inhibitors market share, detailed HER2 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the HER2 inhibitors industry. This HER2 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The HER2 inhibitors market size has grown strongly in recent years. It will grow from $8.77 billion in 2024 to $9.64 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to biotechnological advances, clinical trial success, shift in treatment paradigm, research and development investments, patient outcomes improvement.

The HER2 inhibitors market size is expected to see strong growth in the next few years. It will grow to $13.61 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to patient-centric care models, regulatory changes and approvals, drug resistance management, global market penetration, expanded indications, precision oncology adoption. Major trends in the forecast period include patient advocacy and awareness, clinical trials and research, early detection and diagnosis, precision medicine and biomarker testing, adjuvant and neoadjuvant therapy.

The increasing incidence of breast cancer cases worldwide is expected to be a significant factor contributing to the growth of the HER-2 inhibitors market in the forecast period. As of January 2022, the American Cancer Society reported projections of 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the United States alone. Breast cancer ranks among the four most common types of cancer globally, alongside lung, prostate, and bowel cancer, collectively accounting for 43% of all new cancer cases. Given this rise in breast cancer incidence, there is an anticipated increase in the demand for HER-2 inhibitors in the coming years.

Government initiatives aimed at enhancing breast cancer care and treatment are expected to drive the growth of the HER2 inhibitors market in the future. These initiatives include policies, funding, and programs designed to improve the accessibility, affordability, and quality of care for individuals diagnosed with breast cancer. Such government efforts have increased access to HER2 inhibitors, a treatment for breast cancer, through subsidized programs and research funding, thereby improving care and outcomes for patients. For example, in February 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, unveiled a new Global Breast Cancer Initiative Framework, providing a roadmap to achieve the goal of saving 2.5 million lives from breast cancer by 2040. Consequently, government initiatives to enhance breast cancer care and treatment are fueling the growth of the HER2 inhibitors market.

Prominent companies in the HER2 inhibitor market are strategically concentrating on the development of treatments for specific breast cancer subtypes to gain a competitive advantage. One such focus is on addressing HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer characterized by tumors that do not overexpress or produce an excess of the HER2 protein. In August 2022, AstraZeneca PLC, a leading UK-based pharmaceutical and biotechnology company, achieved a milestone as the U.S. Food and Drug Administration (FDA) granted approval for Enhertu (fam-trastuzumab deruxtecan-nxki). Enhertu is recognized as the first HER2-directed therapy designed for patients with HER2-low metastatic breast cancer. Administered through intravenous infusion, Enhertu is prescribed for adults who have undergone prior metastatic chemotherapy or experienced disease recurrence within six months of completing adjuvant chemotherapy, targeting HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

Major players in the HER2 inhibitor market are directing their efforts towards developing treatments for pre-treated HR+/HER2-metastatic breast cancer. This particular breast cancer subtype, characterized by the presence of hormone receptors (HR+), is the focus of therapeutic development. In February 2023, Gilead Sciences, Inc., a prominent US-based biopharmaceutical company, received approval from the U.S. FDA for Trodelvy (sacituzumab govitecan-hziy). Trodelvy is intended for the treatment of adults with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer. This approval is specifically granted for patients who have undergone prior endocrine-based therapies and two additional systemic treatments in the metastatic setting, addressing the needs of this particular patient population. These strategic initiatives underline the companies' commitment to developing targeted therapies for specific breast cancer subtypes, contributing to their competitive positioning in the HER2 inhibitor market.

In December 2023, Pfizer, a US-based multinational pharmaceutical and biotechnology company, acquired Seagen for around $43 billion. This acquisition is intended to strengthen Pfizer's leadership in oncology by incorporating Seagen's advanced cancer treatments and technologies. This strategic move aims to expedite the development of transformative therapies for cancer patients. Seagen is a US-based biotechnology firm that specializes in providing HER2 inhibitors.

Major companies operating in the HER2 inhibitors market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly International Corp., C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Catalent Inc., Ipsen SA, the Pierre Fabre Group, Biocon Biopharmaceuticals Pvt. Ltd., Innovent Biologics Inc., Halozyme Therapeutics Inc., Seattle Genetics Inc., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Mersana Therapeutics Inc., Cellestia Biotech AG

North America was the largest region in the HER2 inhibitors market in 2024. Middle East is expected to be the fastest-growing region in the HER2 inhibitors market report during the forecast period. The regions covered in the her2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the her2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The HER2 inhibitor market consists of sales of lapatinib, neratinib, tucatinib, and pyrotinib. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2 Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2 inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2 inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2 inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: Monotherapy; Combination Therapy
2) By Application: Squamous Cell Carcinoma; Adenocarcinoma; Large Cell Carcinoma; Breast Cancer; Other Applications
3) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Monotherapy: Single-Agent HER2 Inhibitors; Targeted HER2 Therapies
2) By Combination Therapy: HER2 Inhibitors Combined With Chemotherapy; HER2 Inhibitors Combined With Targeted Therapies; HER2 Inhibitors Combined With Hormonal Therapies
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33004

1. Executive Summary

2. HER2 Inhibitors Market Characteristics

3. HER2 Inhibitors Market Trends And Strategies

4. HER2 Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2 Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global HER2 Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global HER2 Inhibitors Market Growth Rate Analysis
5.4. Global HER2 Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global HER2 Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global HER2 Inhibitors Total Addressable Market (TAM)

6. HER2 Inhibitors Market Segmentation

6.1. Global HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.2. Global HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Squamous Cell Carcinoma
Adenocarcinoma
Large Cell Carcinoma
Breast Cancer
Other Applications
6.3. Global HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Other End Users
6.4. Global HER2 Inhibitors Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Agent HER2 Inhibitors
Targeted HER2 Therapies
6.5. Global HER2 Inhibitors Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HER2 Inhibitors Combined With Chemotherapy
HER2 Inhibitors Combined With Targeted Therapies
HER2 Inhibitors Combined With Hormonal Therapies

7. HER2 Inhibitors Market Regional And Country Analysis

7.1. Global HER2 Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global HER2 Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2 Inhibitors Market

8.1. Asia-Pacific HER2 Inhibitors Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2 Inhibitors Market

9.1. China HER2 Inhibitors Market Overview
9.2. China HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2 Inhibitors Market

10.1. India HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2 Inhibitors Market

11.1. Japan HER2 Inhibitors Market Overview
11.2. Japan HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2 Inhibitors Market

12.1. Australia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2 Inhibitors Market

13.1. Indonesia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2 Inhibitors Market

14.1. South Korea HER2 Inhibitors Market Overview
14.2. South Korea HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2 Inhibitors Market

15.1. Western Europe HER2 Inhibitors Market Overview
15.2. Western Europe HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2 Inhibitors Market

16.1. UK HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2 Inhibitors Market

17.1. Germany HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2 Inhibitors Market

18.1. France HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2 Inhibitors Market

19.1. Italy HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2 Inhibitors Market

20.1. Spain HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2 Inhibitors Market

21.1. Eastern Europe HER2 Inhibitors Market Overview
21.2. Eastern Europe HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2 Inhibitors Market

22.1. Russia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2 Inhibitors Market

23.1. North America HER2 Inhibitors Market Overview
23.2. North America HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2 Inhibitors Market

24.1. USA HER2 Inhibitors Market Overview
24.2. USA HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2 Inhibitors Market

25.1. Canada HER2 Inhibitors Market Overview
25.2. Canada HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2 Inhibitors Market

26.1. South America HER2 Inhibitors Market Overview
26.2. South America HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2 Inhibitors Market

27.1. Brazil HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2 Inhibitors Market

28.1. Middle East HER2 Inhibitors Market Overview
28.2. Middle East HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2 Inhibitors Market

29.1. Africa HER2 Inhibitors Market Overview
29.2. Africa HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2 Inhibitors Market Competitive Landscape And Company Profiles

30.1. HER2 Inhibitors Market Competitive Landscape
30.2. HER2 Inhibitors Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. HER2 Inhibitors Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Eli Lilly International Corp.
31.6. C.H. Boehringer Sohn AG & Co. KG
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Daiichi Sankyo Company Limited
31.9. Catalent Inc.
31.10. Ipsen SA
31.11. the Pierre Fabre Group
31.12. Biocon Biopharmaceuticals Pvt. Ltd.
31.13. Innovent Biologics Inc.
31.14. Halozyme Therapeutics Inc.
31.15. Seattle Genetics Inc.

32. Global HER2 Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2 Inhibitors Market

34. Recent Developments In The HER2 Inhibitors Market

35. HER2 Inhibitors Market High Potential Countries, Segments and Strategies

35.1 HER2 Inhibitors Market In 2029 - Countries Offering Most New Opportunities
35.2 HER2 Inhibitors Market In 2029 - Segments Offering Most New Opportunities
35.3 HER2 Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer